Answers are grounded in this paper and cite their sources.
This study analyzes 22 fetuses with 15q11.2 BP1-BP2 microdeletion syndrome in Eastern China to investigate the prenatal clinical features and postnatal outcomes. We conducted a retrospective study of 22 fetuses diagnosed with 15q11.2 BP1-BP2 microdeletion (312–855 kilobase) via chromosomal microarray analysis among 2607 prenatal cases from January 2022 to September 2024. Parental origin, ultrasound findings, and postnatal outcomes were evaluated. The 15q11.2 BP1-BP2 microdeletion prevalence was 0.84% (22/2607). Prenatal ultrasound anomalies were observed in 54.5% (12/22), primarily mild cardiac findings (tricuspid regurgitation), choroid plexus cysts, and thickened nuchal translucency. Parental testing (13 cases) revealed 6 paternal, 6 maternal, and 1 de novo case. Postnatal follow-up of 18 live births (mean 14.7 months) showed normal development in most cases (17/18), with 1 child exhibiting delayed language development. Four pregnancies (18.2%) were terminated despite genetic counseling. Our study underscores that the 15q11.2 BP1-BP2 microdeletion exhibits incomplete penetrance and variable prenatal phenotypes, complicating outcome prediction. Long-term pediatric follow-up is essential, and early reassurance should be avoided even in cases with normal prenatal findings or favorable short-term outcomes.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: